The Orphan Nuclear Receptor EAR-2 (NR2F6) Inhibits Hematopoietic Cell Differentiation and Induces Myeloid Dysplasia in Vivo
Overview
Authors
Affiliations
Background: In patients with myelodysplastic syndrome (MDS), bone marrow cells have an increased predisposition to apoptosis, yet MDS cells outcompete normal bone marrow (BM)-- suggesting that factors regulating growth potential may be important in MDS. We previously identified v-Erb A related-2 (EAR-2, NR2F6) as a gene involved in control of growth ability.
Methods: Bone marrow obtained from C57BL/6 mice was transfected with a retrovirus containing EAR-2-IRES-GFP. Ex vivo transduced cells were flow sorted. In some experiments cells were cultured in vitro, in other experiments cells were injected into lethally irradiated recipients, along with non-transduced bone marrow cells. Short-hairpin RNA silencing EAR-2 was also introduced into bone marrow cells cultured ex vivo.
Results: Here, we show that EAR-2 inhibits maturation of normal BM in vitro and in vivo and that EAR-2 transplant chimeras demonstrate key features of MDS. Competitive repopulation of lethally irradiated murine hosts with EAR-2-transduced BM cells resulted in increased engraftment and increased colony formation in serial replating experiments. Recipients of EAR-2-transduced grafts had hypercellular BM, erythroid dysplasia, abnormal localization of immature precursors and increased blasts; secondary transplantation resulted in acute leukemia. Animals were cytopenic, having reduced numbers of erythrocytes, monocytes and granulocytes. Suspension culture confirmed that EAR-2 inhibits granulocytic and monocytic differentiation, while knockdown induced granulocytic differentiation. We observed a reduction in the number of BFU-E and CFU-GM colonies and the size of erythroid and myeloid colonies. Serial replating of transduced hematopoietic colonies revealed extended replating potential in EAR-2-overexpressing BM, while knockdown reduced re-plating ability. EAR-2 functions by recruitment of histone deacetylases, and inhibition of differentiation in 32D cells is dependent on the DNA binding domain.
Conclusions: This data suggest that NR2F6 inhibits maturation of normal BM in vitro and in vivo and that the NR2F6 transplant chimera system demonstrates key features of MDS, and could provide a mouse model for MDS.
NR2F6 regulates stem cell hematopoiesis and myelopoiesis in mice.
Woelk J, Narasimhan H, Pfeifhofer-Obermair C, Schraml B, Hermann-Kleiter N Front Immunol. 2025; 15():1404805.
PMID: 39840064 PMC: 11747239. DOI: 10.3389/fimmu.2024.1404805.
Proppe L, Jagomast T, Beume S, Klapper L, Gitas G, Koster F J Cancer Res Clin Oncol. 2023; 149(10):7155-7164.
PMID: 36884115 PMC: 10374721. DOI: 10.1007/s00432-023-04632-2.
Klepsch V, Siegmund K, Baier G Cancers (Basel). 2021; 13(11).
PMID: 34073258 PMC: 8197903. DOI: 10.3390/cancers13112600.
Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy.
Klepsch V, Pommermayr M, Humer D, Brigo N, Hermann-Kleiter N, Baier G Cell Commun Signal. 2020; 18(1):8.
PMID: 31937317 PMC: 6961368. DOI: 10.1186/s12964-019-0454-z.